Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +1.33% PS Ratio is 1.89 as of Aug. 03, 2026, which is 23% below its 10-year median of 2.47. The stock has 1 warning sign investors should review. Among 200 Medical Diagnostics & Research companies, Invitro International ranks better than 63% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Invitro International's share price is $0.0679.
Invitro International's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.04. Hence, Invitro International's PS Ratio for today is 1.89.
The historical rank and industry rank for Invitro International's PS Ratio or its related term are showing as below:
IVRO'
s PS Ratio Range Over the Past 10 Years
Min: 1.41 Med: 2.47 Max: 12.5
Current: 1.89
During the past 9 years, Invitro International's highest PS Ratio was 12.50. The lowest was 1.41. And the median was 2.47.
IVRO's PS Ratio is ranked better than 63% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.7
vs IVRO: 1.89
Invitro International revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Invitro International was 2.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -25.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -34.50% per year.
During the past 9 years, Invitro International's highest 3-Year average Revenue per Share Growth Rate was 3.40% per year. The lowest was -38.60% per year. And the median was -29.45% per year.
Invitro International (OTCPK:IVRO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Invitro International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's PS Ratio distribution charts can be found below:
* The bar in red indicates where Invitro International's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Invitro International's Share Price of today is $0.0679. Invitro International's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Invitro International (IVRO) has a PS Ratio of 1.89 as of Aug. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Invitro International and its competitors. This is 23% below median its historical median of 2.47. Over the past decade, Invitro International's PS Ratio has ranged from 1.41 to 12.50. According to the industry distribution chart, Invitro International ranks #74 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 37%.
Is Invitro International's PS Ratio too high?
Invitro International's current PS Ratio of 1.89 is 23% below median its 10-year median of 2.47. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 12.50. The Medical Diagnostics & Research industry median PS Ratio is 2.70. Invitro International's value of 1.89 is 30% below this industry median. Based on the distribution chart, Invitro International ranks #74 out of 200 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Invitro International's PS Ratio compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #74 out of 200 companies for PS Ratio. This puts Invitro International in the upper half of its industry. The industry median PS Ratio is 2.70. Invitro International's value of 1.89 is 30% below this benchmark. Historically, Invitro International's own PS Ratio has ranged from 1.41 to 12.50 over the past decade. While the company's 10-year median is 2.47 vs. the industry median of 2.70, Invitro International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.70, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current PS Ratio of 1.89 is 30% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current PS Ratio is 1.89, which is 23% below median its own 10-year median of 2.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current PS Ratio is 1.89, which is 23% below median its 10-year median of 2.47 and 30% below the Medical Diagnostics & Research industry median of 2.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Invitro International (IVRO), the current PS Ratio is 1.89 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
